No increase in privatisation offer, Singapore Paincare confirms

The scheme document, including the notice of the scheme meeting, will be dispatched in due course.

The key shareholders of Singapore Paincare Holdings do not intend to increase the scheme consideration of $0.16 each to take the company private, according to a bourse filing on June 10.

“Therefore, by Rule 20.2 of the Code, save where a competitive situation arises, the offeror will not be allowed to subsequently revise the scheme consideration,” Singapore Paincare said.

The scheme document containing full details of the scheme including the notice of the scheme meeting will be despatched in due course.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia